von Willebrand factor human

Von Willebrand factor human is a plasma-derived glycoprotein used to treat and prevent bleeding episodes in patients with von Willebrand disease (VWD) and hemophilia A. It plays a critical role in hemostasis by mediating platelet adhesion and aggregation at sites of vascular injury and stabilizing coagulation factor VIII. By supplementing deficient or dysfunctional endogenous vWF, this therapy restores normal clotting function in affected individuals. Von Willebrand factor human is typically administered intravenously and may be used alone or as part of combination products with antihemophilic factor VIII. The drug was first approved by the FDA in 2015 for use in managing bleeding associated with VWD[2][5][6][8].

Brand names

AlphanateHumate-PWilate

Other names

vWFvon Willebrand factor (human)plasma-derived von Willebrand factor